BIOVF (BIOVF) Stock Price & Analysis
BIOVF (BIOVF) rose 0.00% to USD 49.03 as of July 25, 2026 at 03:08 UTC, according to Nexqual real-time market data.
BIOVF last closed at USD 49.03; the session ranged USD 47.35–47.35 on volume of 200 shares. Market capitalization is $17.10B, with a 52-week range of USD 28.94–49.03 (PNK). Source: Nexqual, July 25, 2026 at 03:08 UTC.
Key Statistics (as of July 25, 2026 at 03:08 UTC)
| Price | USD 49.03 |
|---|---|
| Change | ▲ 0.00% (up) |
| Previous Close | USD 49.03 |
| Open | USD 47.35 |
| Day Range | USD 47.35 – 47.35 |
| 52-Week Range | USD 28.94 – 49.03 |
| Volume | 200 shares |
| Market Cap | $17.10B |
| Exchange | PNK |
Technical Analysis (BIOVF)
Nexqual's technical model rates BIOVF "BUY" based on 5 bullish and 2 bearish signals across 124 daily candles, as of July 25, 2026 at 03:08 UTC.
| Overall Signal | BUY |
|---|---|
| RSI (14) | 100 (overbought) |
| vs SMA50 | Above (USD 48.06) |
| MACD | 0.4 (positive) |
Analyst Ratings (BIOVF)
Wall Street analysts rate BIOVF "None", per Nexqual as of July 25, 2026 at 03:08 UTC.
| Consensus Rating | None |
|---|
Earnings (BIOVF)
| Next Earnings Date | 2026-07-16 |
|---|---|
| Revenue Estimate | $9.05B |
Source: Nexqual, July 25, 2026 at 03:08 UTC.
Financials & Fundamentals (BIOVF)
| Revenue Growth (YoY) | +27.00% |
|---|---|
| Gross Margin | +78.49% |
| Operating Margin | +0.00% |
| Profit Margin | +4.51% |
| ROE | +3.40% |
| Debt / Equity | 41.61 |
| Current Ratio | 0.88 |
| Free Cash Flow | $3.42B |
Source: Nexqual, July 25, 2026 at 03:08 UTC.
Financial Health Score (BIOVF)
Nexqual rates BIOVF's overall financial health "Mixed" across five dimensions, as of July 25, 2026 at 03:08 UTC.
| Growth | Solid — Revenue +8% YoY (annual) |
|---|---|
| Profitability | Strong — Gross margin 78%, operating 0% |
| Balance Sheet | Mixed — Debt/Equity 0.4x |
| Cash Flow | Solid — FCF $3.42B, 12% margin |
| Efficiency | Weak — ROE 3%, ROA 7.7% |
Ownership (BIOVF)
| Insider Ownership | +10.05% |
|---|---|
| Institutional Ownership | +74.55% |
| Shares Outstanding | 347.29M |
| Float | 223.27M |
Source: Nexqual, July 25, 2026 at 03:08 UTC.
Leadership (BIOVF)
BIOVF is led by Guido Oelkers (age 60), CEO & President, per Nexqual as of July 25, 2026 at 03:08 UTC.
| CEO & President | Guido Oelkers (age 60) |
|---|---|
| Chief Financial Officer | Henrik Stenqvist M.Sc. (age 58) |
Major Backers & Investors (BIOVF)
Notable institutional backers of BIOVF include Fidelity, Artisan Partners Funds Inc.-Artisan International Small-Mid Fund, Charles Schwab, according to Nexqual as of July 25, 2026 at 03:08 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Fidelity | 0.56% |
| Artisan Partners Funds Inc.-Artisan International Small-Mid Fund | 0.22% |
| Charles Schwab | 0.13% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 1.75% |
| BlackRock | 0.67% |
Source: Nexqual, July 25, 2026 at 03:08 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| IPSEY | Ipsen S.A. | USD 47.11 | ▲ 0% |
| HKMPF | Hikma Pharmaceuticals plc. | USD 20.37 | ▲ 0% |
| APNHY | Aspen Pharmacare Holdings plc | USD 9.07 | ▲ 0% |
| HKMPY | Hikma Pharmaceuticals plc. | USD 41.27 | ▼ 1.78% |
| SGIOY | Shionogi & Co. Ltd. | USD 8.7 | ▼ 0.57% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 03:08 UTC. This page is informational and not investment advice.